Acromegaly [clinicaltrials_resource:005e837817c21a0393b99843cbfee450]
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly [clinicaltrials:NCT00001860]The Treatment and Natural History of Acromegaly [clinicaltrials:NCT00001981]Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly [clinicaltrials:NCT00004332]Measurement of Outcome of Surgical Treatment in Patients With Acromegaly [clinicaltrials:NCT00005100]Pegvisomant And Sandostatin LAR Combination Study [clinicaltrials:NCT00068029]A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly [clinicaltrials:NCT00068042]Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients [clinicaltrials:NCT00088582]Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients [clinicaltrials:NCT00128232]Long Term Study With B2036-PEG [clinicaltrials:NCT00143416]Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction [clinicaltrials:NCT00145405]Somatuline Autogel: Acromegaly Self/Partner Injection Study [clinicaltrials:NCT00149188]Canadian Pegvisomant Compassionate Study In Acromegalic Patients [clinicaltrials:NCT00151437]An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly [clinicaltrials:NCT00171730]Octreotide Efficacy and Safety in First-line Acromegalic Patients [clinicaltrials:NCT00171886]clinicaltrials:NCT00182091Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients [clinicaltrials:NCT00210457]Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR [clinicaltrials:NCT00216398]Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly [clinicaltrials:NCT00225979]A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide [clinicaltrials:NCT00234520]Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly [clinicaltrials:NCT00234572]Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas [clinicaltrials:NCT00242541]Estrogen Treatment in Acromegalic Women [clinicaltrials:NCT00315107]clinicaltrials:NCT00372697Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly [clinicaltrials:NCT00376064]Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [clinicaltrials:NCT00383708]Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly [clinicaltrials:NCT00444873]Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease [clinicaltrials:NCT00446082]clinicaltrials:NCT00447499Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly [clinicaltrials:NCT00461149]Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA [clinicaltrials:NCT00461188]Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States [clinicaltrials:NCT00461240]Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly [clinicaltrials:NCT00499993]Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery [clinicaltrials:NCT00500227]Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) [clinicaltrials:NCT00517491]clinicaltrials:NCT00521300Physiopathology of Sodium Retention in Acromegaly [clinicaltrials:NCT00531908]clinicaltrials:NCT00552071Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant [clinicaltrials:NCT00552851]Acute Application of Pegvisomant and Octreotide in Acromegaly [clinicaltrials:NCT00595140]clinicaltrials:NCT00600886
condition [clinicaltrials_vocabulary:condition]
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly [clinicaltrials:NCT00001860]The Treatment and Natural History of Acromegaly [clinicaltrials:NCT00001981]Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly [clinicaltrials:NCT00004332]Measurement of Outcome of Surgical Treatment in Patients With Acromegaly [clinicaltrials:NCT00005100]A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome [clinicaltrials:NCT00017927]Pegvisomant And Sandostatin LAR Combination Study [clinicaltrials:NCT00068029]A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly [clinicaltrials:NCT00068042]Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients [clinicaltrials:NCT00088582]Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients [clinicaltrials:NCT00128232]Long Term Study With B2036-PEG [clinicaltrials:NCT00143416]Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction [clinicaltrials:NCT00145405]Somatuline Autogel: Acromegaly Self/Partner Injection Study [clinicaltrials:NCT00149188]Canadian Pegvisomant Compassionate Study In Acromegalic Patients [clinicaltrials:NCT00151437]An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly [clinicaltrials:NCT00171730]Octreotide Efficacy and Safety in First-line Acromegalic Patients [clinicaltrials:NCT00171886]clinicaltrials:NCT00182091Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients [clinicaltrials:NCT00210457]Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR [clinicaltrials:NCT00216398]Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly [clinicaltrials:NCT00225979]A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide [clinicaltrials:NCT00234520]Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly [clinicaltrials:NCT00234572]Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas [clinicaltrials:NCT00242541]Estrogen Treatment in Acromegalic Women [clinicaltrials:NCT00315107]clinicaltrials:NCT00372697Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly [clinicaltrials:NCT00376064]Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [clinicaltrials:NCT00383708]Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly [clinicaltrials:NCT00444873]Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease [clinicaltrials:NCT00446082]clinicaltrials:NCT00447499Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly [clinicaltrials:NCT00461149]Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA [clinicaltrials:NCT00461188]Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States [clinicaltrials:NCT00461240]Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly [clinicaltrials:NCT00499993]Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery [clinicaltrials:NCT00500227]Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) [clinicaltrials:NCT00517491]clinicaltrials:NCT00521300Physiopathology of Sodium Retention in Acromegaly [clinicaltrials:NCT00531908]clinicaltrials:NCT00552071Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant [clinicaltrials:NCT00552851]Acute Application of Pegvisomant and Octreotide in Acromegaly [clinicaltrials:NCT00595140]
condition browse [clinicaltrials_vocabulary:condition-browse]
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly [clinicaltrials:NCT00001860]The Treatment and Natural History of Acromegaly [clinicaltrials:NCT00001981]Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly [clinicaltrials:NCT00004332]Measurement of Outcome of Surgical Treatment in Patients With Acromegaly [clinicaltrials:NCT00005100]A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome [clinicaltrials:NCT00017927]Pegvisomant And Sandostatin LAR Combination Study [clinicaltrials:NCT00068029]A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly [clinicaltrials:NCT00068042]Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients [clinicaltrials:NCT00088582]Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients [clinicaltrials:NCT00128232]Long Term Study With B2036-PEG [clinicaltrials:NCT00143416]Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction [clinicaltrials:NCT00145405]Somatuline Autogel: Acromegaly Self/Partner Injection Study [clinicaltrials:NCT00149188]Canadian Pegvisomant Compassionate Study In Acromegalic Patients [clinicaltrials:NCT00151437]An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly [clinicaltrials:NCT00171730]Octreotide Efficacy and Safety in First-line Acromegalic Patients [clinicaltrials:NCT00171886]clinicaltrials:NCT00182091Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients [clinicaltrials:NCT00210457]Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR [clinicaltrials:NCT00216398]Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly [clinicaltrials:NCT00225979]A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide [clinicaltrials:NCT00234520]Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly [clinicaltrials:NCT00234572]Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas [clinicaltrials:NCT00242541]Estrogen Treatment in Acromegalic Women [clinicaltrials:NCT00315107]clinicaltrials:NCT00372697Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly [clinicaltrials:NCT00376064]Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [clinicaltrials:NCT00383708]Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly [clinicaltrials:NCT00444873]Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease [clinicaltrials:NCT00446082]clinicaltrials:NCT00447499Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly [clinicaltrials:NCT00461149]Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA [clinicaltrials:NCT00461188]Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States [clinicaltrials:NCT00461240]Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly [clinicaltrials:NCT00499993]Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery [clinicaltrials:NCT00500227]Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) [clinicaltrials:NCT00517491]clinicaltrials:NCT00521300Physiopathology of Sodium Retention in Acromegaly [clinicaltrials:NCT00531908]clinicaltrials:NCT00552071Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant [clinicaltrials:NCT00552851]Acute Application of Pegvisomant and Octreotide in Acromegaly [clinicaltrials:NCT00595140]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Acromegaly [clinicaltrials_resource:005e837817c21a0393b99843cbfee450]
Bio2RDF identifier
005e837817c21a0393b99843cbfee450
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:005e837817c21a0393b99843cbfee450
identifier
clinicaltrials_resource:005e837817c21a0393b99843cbfee450
title
Acromegaly
@en
type
label
Acromegaly [clinicaltrials_resource:005e837817c21a0393b99843cbfee450]
@en
Acromegaly